Abstract
Cancer is a global concern leading to millions of deaths every year. A declining trend in new drug discovery and development is becoming one of the major issues among the pharmaceutical, biotechnology industries and regulatory agencies. New drug development is proven to be a very lengthy and a costly process. Launch of a new drug takes 8-12 years and huge investments. Success rate in oncology therapeutics is also low due to toxicities at the pre-clinical and clinical trials level. Many oncological drugs get rejected at very promising stage showing adverse reactions on healthy cells. Thus, exploring new therapeutic benefits of the existing, shelved drugs for their anti-cancerous action could result in a therapeutic approach preventing the toxicities which occurs during clinical trials. Drug repurposing has the potential to overcome the challenges faced via conventional way of drug discovery and is becoming an area of interest for researchers and scientists. Although very few in vivo studies are conducted to prove the anti-cancerous activity of the drugs. Insufficient in vivo animal studies and lack of human clinical trials are the lacuna in the field of drug repurposing. This review focuses on the aspect of drug repurposing for cancer therapeutics. There are various studies which show that drugs approved for clinical indications other than cancer have shown promising anti-cancer activities. Some of the commonly used drugs like Benzodiazepines (Diazepam, Midzolam), Antidepressants (Imipramine, Clomipramine, and Citalopram), Antiepileptic (Valporic acid, Phenytoin), Anti diabetics (metformin) etc., have been reported to show potential activity against the cancerous cells.
Keywords: Drug Repurposing, non-cancerous drugs, secondary indication, anti cancerous activity, cancer therapeutics, drug development, new drug, costly process.
Current Pharmaceutical Design
Title:Anti-Cancer Potential of Some Commonly Used Drugs
Volume: 27 Issue: 45
Author(s): Pallavi Kumari and Shweta Dang*
Affiliation:
- Department of Biotechnology, Jaypee Institute of Information Technology, NOIDA, U.P.,India
Keywords: Drug Repurposing, non-cancerous drugs, secondary indication, anti cancerous activity, cancer therapeutics, drug development, new drug, costly process.
Abstract: Cancer is a global concern leading to millions of deaths every year. A declining trend in new drug discovery and development is becoming one of the major issues among the pharmaceutical, biotechnology industries and regulatory agencies. New drug development is proven to be a very lengthy and a costly process. Launch of a new drug takes 8-12 years and huge investments. Success rate in oncology therapeutics is also low due to toxicities at the pre-clinical and clinical trials level. Many oncological drugs get rejected at very promising stage showing adverse reactions on healthy cells. Thus, exploring new therapeutic benefits of the existing, shelved drugs for their anti-cancerous action could result in a therapeutic approach preventing the toxicities which occurs during clinical trials. Drug repurposing has the potential to overcome the challenges faced via conventional way of drug discovery and is becoming an area of interest for researchers and scientists. Although very few in vivo studies are conducted to prove the anti-cancerous activity of the drugs. Insufficient in vivo animal studies and lack of human clinical trials are the lacuna in the field of drug repurposing. This review focuses on the aspect of drug repurposing for cancer therapeutics. There are various studies which show that drugs approved for clinical indications other than cancer have shown promising anti-cancer activities. Some of the commonly used drugs like Benzodiazepines (Diazepam, Midzolam), Antidepressants (Imipramine, Clomipramine, and Citalopram), Antiepileptic (Valporic acid, Phenytoin), Anti diabetics (metformin) etc., have been reported to show potential activity against the cancerous cells.
Export Options
About this article
Cite this article as:
Kumari Pallavi and Dang Shweta *, Anti-Cancer Potential of Some Commonly Used Drugs, Current Pharmaceutical Design 2021; 27 (45) . https://dx.doi.org/10.2174/1381612827666210622104821
DOI https://dx.doi.org/10.2174/1381612827666210622104821 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Cell Adhesion Molecules: Structure, Function, Drug Design, and Biomaterials (Executive Editor: Seetharama D. Satyanarayanajois)]
Current Pharmaceutical Design Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies Chemopreventive and Chemotherapeutic Potential of Curcumin in Breast Cancer
Current Drug Targets Advances in the Development of Virus-Like Particles as Tools in Medicine and Nanoscience
Current Chemical Biology Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis in Diabetes and Cancer
Infectious Disorders - Drug Targets Cervical Cancer and Human Papillomaviruses: Inactivation of Retinoblastoma and Other Tumor Suppressor Pathways
Current Molecular Medicine Hypoxia and Oxidative Stress in the Pathogenesis of Gynecological Cancers and in Therapeutical Options
Current Cancer Therapy Reviews Current Highlights About the Safety of Inorganic Nanomaterials in Healthcare
Current Medicinal Chemistry Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Development of Human Papillomavirus (HPV) Vaccines: A Review of Literature and Clinical Update
Reviews on Recent Clinical Trials Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets PET-MRI Based Molecular Imaging as a Response Marker in Cervical Cancer: A Systematic Review
Current Molecular Imaging (Discontinued) The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
Current Medicinal Chemistry